Kornimate/medical-research-clean huggingface dataset:
beneficial and harmful effects of reducing public suicide stigma

Conditions: Public Suicide Stigma

Summary: there is growing evidence that negative attitudes towards persons affected by suicide (i.e. persons who experience suicidality, persons who lost a loved one to suicide), so called public suicide stigma, is harmful for suicide prevention, for example by reducing social support, inhibiting help-seeking for suicidality and increasing distress as well as suicidality among stigmatized persons. reducing public suicide stigma could therefore be an important factor of successful suicide prevention. however, reducing public suicide stigma could also be harmful, for example by increasing attitudes that suicidal behaviour is a normal and acceptable solution for crisis situations, which could decrease help-seeking for suicidality and encourage suicidal behaviour. this project will (1) develop four interventions (contact-based vs. education based, video vs. text) hypothesized to reduce public suicide stigma, (2) determine the efficacy of the four interventions with regard to reducing public suicide stigma, (3) identify additional harmful (e.g. normalization of suicidal behaviour) and beneficial intervention effects (e.g. improved attitudes to seek help) and (4) investigate pathways explaining intervention effects.


Eligibility criteria:
inclusion criteria: participants need to be at least 18 years old, speak german and provide online informed consent. exclusion criteria: persons who self-report to have experienced suicidality within three months before baseline will be excluded.

Keywords: suicide stigma general public suicide prevention
thrombotic biomarkers to predict thrombosis in heparin-induced thrombocytopenia

Conditions: Heparin-Induced Thrombocytopenia; Thrombosis; Biomarkers

Summary: heparin induced thrombocytopenia (hit) is a kind of catastrophic thrombotic complications after the application of heparin. if hit without treatment, death rate is as high as 30% to 50%. early diagnosis of hit and prevention of thrombosis is very important. this study is planned to assess the use of thrombotic biomarkers in patients with hit, including thrombin-antithrombin complex, d-dimer, fibrin degradation products and thrombelastograghy monitoring . these biomarkers are monitored in 5-14 days post-operation to assess the risk of thrombosis in hit patients. all patients were followed up for 30 days, and clinical outcomes, including new thrombus and death, were recorded during follow-up.


Eligibility criteria:
inclusion criteria: * hospitalized patients undergoing cardiac surgery. * receiving unfractionated heparin anticoagulation. exclusion criteria: * history of heparin-induced thrombocytopenia * pregnant woman

Keywords: heparin-induced thrombocytopenia thrombosis thrombin-antithrombin d-dimer thrombelastograghy
research on effectiveness and safety of the treatment, hyperthermic intraperitoneal chemotherapy combined with tislelizumab and targeted therapy, that is used for high-risk hepatocellular carcinoma after r0 resection

Conditions: Hepatocellular Carcinoma

Summary: there are limited treatment options for hcc with high recurrence risk, and there is no consistent plan for adjuvant therapy after surgery. hence an unmet clinical need. based on previous studies on unresectable hcc patients combined with targeted and immunotherapy, it has been found that the effect is significant, but the effect of combined with hipec is not clear, and no similar studies have been reported. therefore, this project intends to carry out a single-arm clinical study on the efficacy and safety of hipec + tislelizumab combined with targeted therapy for high recurrence risk hcc. and observe the clinical benefits, to provide new ideas and evidence-based basis for the treatment of hcc with high recurrence risk.


Eligibility criteria:
inclusion criteria: * (1) in line with the diagnostic criteria of western medicine, the pathological section was diagnosed as hcc; imaging and intraoperative exploration of hcc patients with high risk of recurrence: multiple tumors or satellite lesions, tumor diameter\>5cm, hcc rupture and bleeding, combined with vascular invasion, and serum afp\>32ng/ml. (2)18-70 years (3) liver function: child-pugh a、b (4) patients voluntarily receive treatment with this program. exclusion criteria: * (1) patients did not meet the inclusion criteria. (2) use of other antineoplastic drugs during the follow-up period (3) severe heart and kidney damage. (4) failure to follow the prescription for medication, and unable to judge the efficacy or incomplete information (5) not suitable for targeted therapy and anti-pd1 immunotherapy.

Keywords: high-risk hepatocellular carcinoma; adjuvant therapy; hipec; tislelizumab
cognitive behavioral treatment to reduce alcohol use among hiv-infected kenyans

Conditions: Binge Drinking; Alcohol Abuse; Alcohol Dependence; HIV Infections

Summary: this study will determine whether a cognitive behavioral intervention that demonstrates strong evidence in the u.s. of reducing alcohol use is effective when delivered by paraprofessionals in kenya and compared against a usual care support group.

alcohol use and abuse have been associated with increased risky sexual behavior, poor adherence to antiretroviral therapy (arvs) and toxicity from arvs among those with hiv infection. as such, alcohol use and abuse have a major impact on hiv transmission and disease progression. because alcohol abuse is widespread in kenya, with estimates of hazardous drinking as high as 68% in general medicine clinics and 53% in hiv clinics, this stage 1 pilot project will develop and evaluate a paraprofessionally led group cognitive behavioral treatment (cbt) targeting alcohol use among hiv infected kenyans who were initiated on arv therapy in the past year. although cbt is well-suited to the kenyan setting because it is comparatively structured and consistent with the kenyan conceptual model of drinking behavior, it requires adaptation for group paraprofessional delivery due to the extremely limited supply of kenyan mental health professionals. the goal of this 24-month capacity-building r21 study is to evaluate the efficacy of a novel application of cbt, a 6-session paraprofessionally led group in eldoret, kenya, when compared against a usual care support group, to reduce hazardous and binge drinking among adult persons infected with hiv. this work will be conducted via the kenya-u.s. hiv and alcohol research and prevention partnership-an experienced team of kenyan and u.s. physicians, behavioral scientists, recovered substance users and persons infected with hiv. the team expands on well-established ties between the academic model for providing access to health care (ampath) and the veterans aging cohort study (vacs), a longitudinal clinical study of hiv and alcohol. ampath treats more than 65,000 hiv patients in 19 clinics in western kenya. our goals are to: 1) train kenyan staff and investigators in research methods and train paraprofessionals in group cbt delivery; 2) pilot the cbt adaptation; and 3) evaluate the feasibility of the paraprofessionally led group cbt via a stage 1 trial in which 56 hiv infected kenyans are randomized to same-sex cbt or usual care hiv support groups.

Eligibility criteria:
inclusion criteria: * hiv outpatient * hazardous or binge drinker * drank any alcohol in past month * arv-eligible or initiated on arvs in past 12 months * within 1 hour travel distance of eldoret, kenya hiv clinic * speak kiswahili exclusion criteria: * active psychosis or suicidality * plans to move within next 6 months \> 1 hr travel distance from eldoret hiv clinic * physically unable to attend sessions * ever attended ampath alcohol support group

Keywords: alcohol use hiv cognitive behavioral treatment kenya hazardous/binge drinking alcohol abuse/dependence
automated telehealth diagnostics for remote parkinson monitoring

Conditions: Parkinson's Disease

Summary: the objective is to clinically assess the kinesia homeview system for automated and remote monitoring of parkinson's disease (pd) motor symptoms.

currently, there is limited access to movement disorder specialist centers for a significant portion of the pd population. treatment effectiveness is judged during office visits by improvement of patient motor symptoms and quality of life. clinicians evaluate patients by having them perform specific motor tasks and rating the severity on a 0-4 scale. a major limitation is that a single evaluation in a clinical setting may not accurately reflect motor symptom fluctuations experienced over the course of a day, week, or month. clinicians currently lack effective, affordable medical devices that can be easily delivered to a patient's home for monitoring symptoms on a more continuous basis as motor symptoms typically change throughout the day. kinesia homeview provides a repeatable, automated system clinicians can use to remotely monitor pd motor symptoms on a more continuous basis in a patient's home. the investigators hypothesize use of the kinesia homeview system will improve outcomes and decrease costs especially for patient populations in areas not in close proximity to movement disorder specialists.

Eligibility criteria:
inclusion criteria: * individuals with self-reported clinically-confirmed diagnosis of idiopathic parkinson disease. * be fluent in english * willing and able to provide informed consent exclusion criteria: * inability to carry out study activities * subjects with cognitive deficits that would prevent following instructions and serious medical conditions that would compromise a subject's safety * subjects who have dementia, exhibited by those with a score less than 22 on the montreal cognitive assessment (moca) * subjects with deep brain stimulation (dbs)

Keywords: parkinson's disease telemedicine telehealth kinesia tremor bradykinesia dyskinesia
vaccine therapy in treating patients with stage iiib, stage iiic, or stage iv melanoma

Conditions: Intraocular Melanoma; Melanoma (Skin)

Summary: rationale: vaccines may make the body build an immune response to kill tumor cells. purpose: this randomized phase i/ii trial is studying three different doses of a vaccine and comparing them to see how well they work in treating patients with stage iiib, stage iiic, or stage iv melanoma.

objectives: * determine the immune response in patients with stage iiib, iiic, or iv melanoma treated with vaccine comprising multiple synthetic melanoma peptides, montanide isa-51, and sargramostim (gm-csf). outline: this is a randomized study. patients are randomized to 1 of 3 treatment arms. * arm i: patients receive vaccine comprising low-dose multiple synthetic melanoma peptides, montanide isa-51, and sargramostim (gm-csf) on days 1, 8, 15, 29, 36, and 43. * arm ii: patients receive vaccine comprising medium-dose multiple synthetic melanoma peptides, montanide isa-51, and gm-csf as in arm i. * arm iii: patients receive vaccine comprising high-dose multiple synthetic melanoma peptides, montanide isa-51, and gm-csf as in arm i. on day 22, the lymph node draining the vaccination site is removed to determine whether the immune system is responding to the vaccine. projected accrual: a maximum of 38 patients will be accrued for this study.

Eligibility criteria:
disease characteristics: * diagnosis of stage iiib, iiic, or iv melanoma * hla-dr1, -dr4, -dr11, -dr13, or -dr15 positive * brain metastases allowed at the discretion of the principle investigator patient characteristics: age * 18 and over performance status * ecog 0-1 life expectancy * not specified hematopoietic * absolute neutrophil count \> 1,000/mm\^3 * platelet count \> 100,000/mm \^3 * hemoglobin \> 9 g/dl hepatic * liver function tests ≤ 2.5 times upper limit of normal (uln) renal * creatinine ≤ 1.5 times uln cardiovascular * no new york heart association class iii or iv heart disease other * prior diagnosis of other cancer allowed * not pregnant or nursing * weight ≥ 110 pounds * no uncontrolled diabetes prior concurrent therapy: biologic therapy * more than 4 weeks since prior growth factors * more than 4 weeks since prior allergy shots * more than 12 weeks since prior melanoma vaccine therapy\* note: \*prior melanoma vaccine allowed only for patients with disease progression during or after administration of the vaccine * no prior vaccination with any of the peptides used in this study chemotherapy * more than 4 weeks since prior chemotherapy endocrine therapy * more than 4 weeks since prior steroids radiotherapy * more than 4 weeks since prior radiotherapy surgery * not specified other * more than 1 month since prior investigational drugs or therapies * no other concurrent investigational drugs or therapies

Keywords: stage iii melanoma stage iv melanoma recurrent melanoma ciliary body and choroid melanoma, medium/large size extraocular extension melanoma iris melanoma recurrent intraocular melanoma
serum thyroglobulin as a marker of iodine status during pregnancy

Conditions: Dietary Iodine Deficiency; Thyroid; Functional Disturbance

Summary: the purpose of the investigation is to assess iodine status of pregnant women at week 16 of gestation targeting serum thyroglobulin as a biomarker of iodine deficiency. the investigators aim to assess whether pre-gestational initiation of iodine supplementation is more advantageous in comparison to supplementation start at the time of pregnancy detection.

mild iodine deficiency is still a public health issue in many industrialized countries, especially during pregnancy. during the last decade there was no monitoring of the iodine status in pregnancy in hungary. since urinary iodine concentration (uic) only reflects recent iodine intake and carries limited information on individual existing iodine stores, another biomarker e.g. measurement of serum thyroglobulin concentration, would be useful to gain comprehensive information. in the present study, the purpose of the investigation is to compare uic, uic normalized to creatinine concentration and serum thyroglobulin as biomarkers of iodine supply in pregnant women in a geographical region where previously iodine deficiency had been found. uic, serum thyroglobulin level and thyroid function are measured, and information about iodine supplementation and smoking before and during pregnancy are recorded.

Eligibility criteria:
inclusion criteria: * healthy pregnant women at week 16 of gestation exclusion criteria: * thyroid disease

Keywords: thyroglobulin iodine pregnancy
myeloid cells in aortic valve stenosis

Conditions: Aortic Valve Disease; Aortic Valve Stenosis

Summary: investigators plan to characterize systemic inflammation and circulating immune cells in participants with moderate and severe calcific aortic valve disease and matched healthy controls.

calcific aortic valve disease (cavd) is the most common type of valvular heart disease in the western world. due to the aging of the population, the impact of this disorder is expected to further increase in the next decades. the underlying pathophysiology remains incompletely defined and there are currently no effective medical treatments capable of altering its course, identifying a major unmet need in this growing population of patients. based on the similarities between cavd and atherosclerosis in pathophysiology and shared risk factors, it is now hypothesized that activation of the innate immune system contributes to the development of cavd. therefore, the investigators will perform an observational study to assess the role of activation of the innate immune system in cavd.

Eligibility criteria:
inclusion criteria: * age \> 18 years * mild, moderate or severe degenerative aortic valve stenosis as defined by transthoracic echocardiography according to the 2017 esc/eacts guidelines for the management of valvular heart disease. exclusion criteria: * active auto-inflammatory or auto-immune diseases * anti-inflammatory drugs * vaccination less than one month before inclusion * bone marrow transplantation * active malignancy, except for local basal cell carcinoma or local squamous cell skin carcinoma, that can be treated curatively by excision. * history of endocarditis of the aortic valve * history of radiation therapy aimed at the chest * acute ischemic cardiac event less than three months before inclusion * systemic inflammation less than one month before inclusion with fever and/or for which antibiotics have been prescribed, with the exception for the use of nitrofurantoin for a urinary tract infection without fever

Keywords: calcific aortic valve disease valvular heart disease inflammation innate immune cells
study of levofloxacin-based concomitant therapy for h. pylori eradication in diabetic patients

Conditions: Helicobacter Pylori Infection

Summary: the study aims to evaluate h. pylori eradication rate in diabetic patients by using novel 10-day levofloxacin-based concomitant therapy compared with conventional 10-day sequential therapy.


Eligibility criteria:
inclusion criteria: * diabetic patients with helicobacter pylori infection exclusion criteria: * pregnancy or physically poor performance status * patients with contraindication for upper endoscopy * severe coagulopathy for endoscopic biopsy * chronic kidney disease (egfr \< 50) or end stage renal disease * known allergy to interventional drugs * previous eradication failure

Keywords: helicobacter pylori
timing of cholecystectomy in severe pancreatitis

Conditions: Acute Pancreatitis; Cholelithiasis

Summary: the goal of this clinical trial is to compare outcomes for interval or early laparoscopic cholecystectomy in patients with moderately severe and severe pancreatitis. the main question\[s\] it aims to answer are: * to establish whether there is a difference in surgical outcomes comparing patients diagnosed with severe or moderately severe pancreatitis on which early cholecystectomy was performed versus performing interval cholecystectomy. * the primary endpoint will be to evaluate major complications, defined as a clavien-dindo score greater than or equal to iii/v. * secondary endpoints include evaluating minor complications (defined as a clavien-dindo score below iii/v), biliary disease recurrence, mortality, postoperative hospital stay and postoperative admittance into an intensive care unit. participants will be randomly assigned to either group: early cholecystectomy during the pancreatitis hospitalization or interval cholecystectomy scheduled 4 weeks after clinical resolution of pancreatitis.

chispa is a randomized controlled, parallel-group, superiority clinical trial. an intention- to-treat analysis will be performed. it seeks to evaluate differences between patients taken to early cholecystectomy during hospital admission (72 hours after randomization) versus delayed cholecystectomy (30 +/- 5 days after randomization). primary endpoint is major complications associated to laparoscopic cholecystectomy defined as a clavien-dindo score of over iii/v during the first 90 days after the procedure. secondary endpoints include recurrence of biliary disease, mortality, minor complications (clavien-dindo score below iii/v), days of postoperative hospital stay, and days admitted in an intensive care unit postoperatively.

Eligibility criteria:
inclusion criteria: * age ≥18 years, diagnosis of pancreatitis according to atlanta guidelines, moderately severe or severe pancreatitis (apache score ≥8 on admittance) * biliary pancreatitis diagnosed on imaging (be it ultrasound, magnetic resonance imaging and/or tomography) * recovery of pancreatitis by tolerance of oral intake (defined as 24 hours of food consumption of any consistency without emetic episodes and pain defined as 4/10 on the visual analogue score of pain) and written informed consent. exclusion criteria: * pregnancy * history of cholecystectomy * planned open cholecystectomy * pancreatitis-associated complication before laparoscopic cholecystectomy (compartment syndrome, bleeding and/or need for peripancreatic collection drainage) * chronic pancreatitis, * more than one episode of pancreatitis * active malignant disease * septic shock * choledocholithiasis not resolved by ercp, post-ercp perforation and post-ercp concomitant pancreatitis.

Keywords: cholecystectomy acute pancreatitis cholelithiasis
pain with trigger finger injection: a comparison of steroid alone versus steroid/lidocaine mixture

Conditions: Trigger Finger Disorder

Summary: this research is being done to compare pain relief and efficacy of trigger finger injection using a combination of lidocaine/corticosteroid versus corticosteroid injection alone versus corticosteroid/saline combination.

this is a prospective, randomized study comparing pain relief and efficacy of trigger finger injection using a combination of lidocaine/corticosteroid versus corticosteroid injection alone versus corticosteroid/saline combination.

Eligibility criteria:
inclusion criteria: * age 18-90 * male or female (non-pregnant) * clinically diagnosed trigger digit * subject is able to provide voluntary, written informed consent * subject, in the opinion of the clinical investigator, is able to understand the clinical investigation and is willing to perform all study procedures and follow-up visits. exclusion criteria: * age \ 90 * pregnant or lactating women * non-english speaking individuals * medication contradictions to lidocaine, corticosteroids and/or saline * prior injection or surgery on the affected finger * diagnosis of reflex symptomatic dystrophy (rsd) or complex regional pain syndrome (crps) * open wound

Keywords: flexor tendon entrapment snapping finger trigger digits trigger thumb
vascutek anaconda™ abdominal aortic aneurysm (aaa) post-market surveillance registry

Conditions: Abdominal Aortic Aneurysm

Summary: the purpose of this observational post-market surveillance registry is to gather post-market data on the performance of the ce marked vascutek anaconda™ stent graft system for the repair of abdominal aortic aneurysms (aaa). the study population consists of patients suitable for endovascular repair of aaa. patients will be followed at 1, 3, 6, 12, 18, 24, 36, 48 and 60 months post-implantation.

vascutek limited, a world leader in the development of vascular grafts, has combined their latest technological developments in polyester textile technology with unique endovascular design features to produce anaconda™, the world's next generation of aaa stent graft systems. intuitive and of a modular design, anaconda™ is the only repositionable device which also features exceptional flexibility. the modular design comprises bifurcate bodies, iliac legs and aortic cuffs. nitinol, an alloy of nickel and titanium, has self-expanding properties and forms the top "ring-stent" of the bifurcate body section. the "ring stent" is composed of multiple turns of nitinol wire that provides significantly increased "hoop-strength" enabling a conformable and secure haemostatic seal against the vessel wall to be achieved. nitinol hooks located adjacent to the "ring stent" anchor the graft in position thus preventing graft migration. the iliac limbs are fully supported with nitinol and the bifurcate bodies feature a distal contra-lateral lumen nitinol support, which in conjunction with a unique intrinsic magnet guidewire system facilitates cannulation of the bifurcate section. the system is available in a wide range of sizes thus making it a flexible and adaptable stent graft system with the potential to repair diverse patient anatomy.

Eligibility criteria:
inclusion criteria: * patient is implanted with anaconda™ stent graft system exclusion criteria: * ruptured or symptomatic aneurysm * juxta or suprarenal extension of aneurysm * clinically serious concomitant medical disease or infection * need to sacrifice both internal iliac arteries due to aneurysmal dilatation * connective tissue disease (marfan's syndrome) * asa rating of grade iv or v * known allergy to nitinol, polyester or contrast medium * excessive tortuosity of access vessels (femoral or iliac arteries) * patients with aneurysm neck lengths of less than 15mm